Please use this identifier to cite or link to this item: https://doi.org/10.1155/2016/5347262
Title: Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Authors: Li, F.-F
Gao, G
Li, Q
Zhu, H.-H
Su, X.-F
Wu, J.-D
Ye, L 
Ma, J.-H
Keywords: 8 isoprostaglandin F2 alpha
antidiabetic agent
dapagliflozin
glucose
metformin
placebo
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
8-epi-prostaglandin F2alpha
benzhydryl derivative
glucoside
glycosylated hemoglobin
hemoglobin A1c protein, human
prostaglandin F2 alpha
Article
blood glucose monitoring
clinical article
controlled study
data collection method
diabetic patient
diagnostic test accuracy study
double blind procedure
drug efficacy
drug safety
drug tolerability
glucose blood level
glycemic control
human
hyperglycemia
hypoglycemia
lifestyle modification
non insulin dependent diabetes mellitus
outcome assessment
oxidative stress
patient counseling
phase 3 clinical trial
plasma
prostaglandin blood level
randomized controlled trial
receiver operating characteristic
risk reduction
treatment duration
urinary tract infection
analogs and derivatives
clinical trial
metabolism
non insulin dependent diabetes mellitus
Benzhydryl Compounds
Blood Glucose
Diabetes Mellitus, Type 2
Dinoprost
Double-Blind Method
Glucosides
Glycated Hemoglobin A
Humans
Hypoglycemic Agents
Oxidative Stress
Issue Date: 2016
Citation: Li, F.-F, Gao, G, Li, Q, Zhu, H.-H, Su, X.-F, Wu, J.-D, Ye, L, Ma, J.-H (2016). Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Journal of Diabetes Research 2016 : 5347262. ScholarBank@NUS Repository. https://doi.org/10.1155/2016/5347262
Rights: Attribution 4.0 International
Abstract: Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with H b A 1 c levels of 7.5-10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2α level at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups. Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy (P = 0.010). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG (P = 0.026) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 (P < 0.05, resp.). In addition, plasma 8-iso PGF2α level was notably decreased in the treatment group compared to the control group (P = 0.034). Conclusions. In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system. © 2016 Feng-fei Li et al.
Source Title: Journal of Diabetes Research
URI: https://scholarbank.nus.edu.sg/handle/10635/183370
ISSN: 23146745
DOI: 10.1155/2016/5347262
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2016_5347262.pdf1.34 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

17
checked on Jan 12, 2021

Page view(s)

23
checked on Jan 14, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons